Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199085 | 0.91 | PRKCQ (0.39) | CSNK2A2CSNK2A1SYKLRRK2PRKCQ | |
| SCHEMBL429225 | 0.91 | CSNK2A2 (0.38) | CSNK2A2CSNK2A1SYKLRRK2PRKCQ | |
| SCHEMBL10199063 | 0.88 | CSNK2A2 (0.34) | CSNK2A2CSNK2A1SYKLRRK2PRKCQ | |
| SCHEMBL10199108 | 0.87 | SYK (0.38) | SYKLRRK2PRKCQ | |
| SCHEMBL431511 | 0.87 | CSNK2A2 (0.44) | CSNK2A2CSNK2A1SYKLRRK2PRKCQ | |
| SCHEMBL10199027 | 0.86 | SYK (0.36) | CSNK2A2CSNK2A1SYKPRKCQ | |
| SCHEMBL432560 | 0.85 | SYK (0.51) | SYK | |
| SCHEMBL12539017 | 0.84 | CSNK2A2 (0.35) | CSNK2A2CSNK2A1PRKCQ | |
| SCHEMBL433658 | 0.81 | PRKCQ (0.46) | CSNK2A2CSNK2A1SYKLRRK2PRKCQ | |
| SCHEMBL10199432 | 0.80 | CSNK2A2 (0.38) | CSNK2A2CSNK2A1SYKLRRK2PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181222-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | CSNK2A2 158/4885CSNK2A1 163/4885SYK 600/4885 |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | CSNK2A2 158/4885CSNK2A1 163/4885SYK 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.